ARCHIVES

USC Opts for Its own IL-2 Protocol, Shuns NCI Trial

This article is from The Cancer Letter archive.

Vol. 13 No. 19 | May 8, 1987

Download PDF Visit The Full Archive

Related Articles

Shingleton To Retire As Director Of Duke Comprehensive Center

July 10, 1981

Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression

November 30, 2012

National Breast Cancer Coalition Sets Goal To End Breast Cancer By Jan. 1, 2020

September 24, 2010

FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX

November 27, 1987

Virus Cancer Program Report On Scientific Activities

August 1, 1975

Cedars-Sinai Develops Criteria For FDG-PET In Breast Cancer

August 25, 2006